Podcast
On this episode of Managed Care Cast, we’re bringing you a portion of a panel discussion about the Oncology Care Model, held in July 2019 during a meeting of The Institute for Value-Based Medicine® (IVBM), an initiative of The American Journal of Managed Care®. At IVBM events, we gather thought leaders to share best practices across medicine, pharmacy, and management in regional locations around the country. This podcast is taken from our meeting focusing on Innovation and Quality in Oncology Care.
On this episode of Managed Care Cast, we’re bringing you a portion of a panel discussion about the Oncology Care Model, held in July 2019 during a meeting of The Institute for Value-Based Medicine (IVBM), an initiative of The American Journal of Managed Care®. At IVBM events, we gather thought leaders to share best practices across medicine, pharmacy, and management in regional locations around the country. This podcast is taken from our meeting focusing on Innovation and Quality in Oncology Care.
The wrap-up discussion, focusing largely on the needs of employers as well as patients and caregivers, was led by the moderator of the evening, Iuliana Shapira, MD, chief medical officer for Regional Cancer Care Associates, which is headquartered in New Jersey. Joining her were Kim Woofter, RN, executive vice president, Strategic Alliances and Practice Innovation, Advanced Centers for Cancer Care in Indiana; Barry Russo, chief executive officer at The Center for Cancer and Blood Disorders in Texas; Lani Alison, RN, MS, vice president, Clinical Affairs, at Regional Cancer Care Associates; and Susan Poretta, director of Partner Transformation at Horizon Blue Cross Blue Shield of New Jersey.
Listen above or through one of these podcast services:
Find the latest IVBM event here, including one happening on September 19, 2019 in Philadelphia, Pennsylvania.
Read our previous coverage of IVBM events:
Managing Costs in Diabetes Means Intervening Early to Avoid Complications Later, Experts Say
As Comorbidities Pile Up, True Diabetes Cost Measured by More Than Insulin, Panel Says
How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL